GlassScriptPhysician profile
Jeffrey J Steinberg
NPI 1003222167
$3,698.01
in general payments reported to CMS, 2019-2025
35 companies · $239 in 2025
The $239 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,750 · 2020: $218 · 2021: $318 · 2022: $279 · 2023: $567 · 2024: $326 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $806 · Consulting Fee: $300 · Education: $26.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $805.64 |
| Consulting Fee | $300.00 |
| Education | $26.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $672.14 | 2019-2025 | Tysabri |
| Mdd US Operations, LLC | $409.95 | 2019-2024 | Apokyn, Gocovri, Apokyn |
| Teva Pharmaceuticals USA, INC. | $264.01 | 2019-2023 | Austedo Xr |
| Lilly USA, LLC | $236.32 | 2019-2023 | Reyvow, Emgality |
| Allergan, INC. | $207.25 | 2019 | |
| Abbvie INC. | $165.97 | 2022-2025 | Ubrelvy |
| Novartis Pharmaceuticals Corporation | $148.61 | 2019-2021 | |
| Boston Scientific Corporation | $139.75 | 2019 | |
| Acorda Therapeutics, INC | $136.38 | 2019 | |
| Genzyme Corporation | $125.67 | 2019 | |
| Alexion Pharmaceuticals, INC. | $125.57 | 2022-2024 | Ultomiris |
| Avanir Pharmaceuticals, INC. | $119.70 | 2019-2020 | |
| Eisai INC. | $114.05 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $106.31 | 2019-2020 | |
| Ucb, INC. | $85.39 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $84.58 | 2019-2020 | |
| Sk Life Science, INC. | $66.62 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $58.97 | 2022-2023 | Ponvory |
| Lundbeck LLC | $53.88 | 2023 | Vyepti |
| Genentech USA, INC. | $46.62 | 2019-2023 | Ocrevus, Enspryng |
| Amgen INC. | $44.91 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.92 | 2022 | |
| Pfizer INC. | $31.09 | 2023 | |
| Alnylam Pharmaceuticals INC. | $24.40 | 2019 | |
| Akcea Therapeutics, INC. | $24.04 | 2019 | |
| Blue Earth Diagnostics | $22.65 | 2020 | |
| Ambu INC. | $21.82 | 2020 | |
| Emd Serono, INC. | $19.21 | 2019 | |
| Neurelis, INC. | $17.12 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $16.64 | 2022 | |
| Merck Sharp & Dohme LLC | $16.62 | 2019 | |
| Csl Behring | $14.96 | 2019 | |
| Grifols USA, LLC | $13.90 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.60 | 2021 | |
| Ge Healthcare | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Steinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.